Spurned by FDA, Passage Bio finds exit through merger with Remix

Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in an all-stock reverse merger with RNA specialist Remix Therapeutics.